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Abstract 
Herpes simplex virus type 2 (HSV-2) is widely distributed through the human population, infecting 
more than 500 million people globally. Although causing generally mild infections this virus may cause 
severe symptoms occasionally, mainly in immunocompromised patients. Presently, there are a number 
of systemic antiviral agents against herpesvirus, the most commonly used being acyclovir (ACV) and its 
prodrugs. However, long term treatments with these drugs may result in the development of 
resistance, especially in immunocompromised patients, which leads to a continuous search for new 
and better therapeutic alternatives. According to the World Health Organization (WHO) plants would 
be the best sources for obtaining a wide variety of drugs. In fact, in the last decades many 
pharmacological and chemical studies have focused on medicinal plants and the discovery of new 
natural therapeutic compounds. In this study the anti-herpetic action of an aqueous extract was 
evaluated. The product was obtained by decoction of stem and leaves from Solidago virgaurea, a 
perennial herb member of the Asteraceae family. The study of the aqueous extract activity included a 
preliminary evaluation of its cytotoxicity in Vero cells – by the MTT assay - in the same conditions that 
are applied for viral production. Extract direct effect on viral particles – virucidal effect – was also 
assessed, having proved null. Anti-herpetic activity was investigated through two kinds of experiments: 
treatment of infected cells during virus production that revealed a mean yield reduction of 94 % in 
treated relatively to non-treated cells and an IC50 of 35.1 μg/mL; and treatment of infected cells during 
virus titration, which revealed slighter inhibition but significant size differences between virus plaques 
formed in treated and control conditions (smaller in treatment conditions).  To further evaluate the 
mechanisms that mediate the aqueous extract inhibitory effect, infected cells – treated and non-
treated - and virus particles – produced in treated and non-treated cells - were visualized through 
Transmission Electron Microscopy (TEM), revealing less damage due to infection in treated cells and a 
reduced amount of viral particles in HSV-2 suspensions produced in treated cells, relatively to controls. 
A kinetic of the first hours of the infection was performed with and without treatment, to assess 
possible differences in DNA production. Extracted samples were subjected to qPCR and results showed 
that the amount of viral DNA raises significantly slower in treated versus non-treated infected cells, 
throughout the infection. This is consistent with the effective reduction of the extract when added at 
later infection times - 4-6 h p.i. - when DNA replication is already in an advanced stage. Our results 
suggest that the aqueous extract inhibits HSV-2 replication, when present at the beginning of the 
infection, possibly by interfering with the viral DNA synthesis. 
 
Keywords: HSV-2; Anti-herpetic activity; Asteraceae; Vero cells; Cytotoxicity  
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Resumo 
O vírus Herpes simples tipo 2 (HSV-2) é um vírus de simetria icosaédrica e grandes dimensões, 
pertencente à família Herpesviridae, subfamília Alphaherpesvirinae da ordem Herpesvirales. Infecta 
mais de 500 milhões de pessoas em todo o mundo, surgindo, em cada ano, mais de 20 milhões de 
casos. A sua prevalência é geralmente mais elevada entre mulheres do que homens e varia 
substancialmente entre diferentes regiões do globo, alcançando os mínimos na Europa Ocidental - 18 
% para mulheres e 13 % para homens – e percentagens máximas na África Subsaariana – 70 % para 
mulheres e 55 % para homens. O HSV infecta as células da mucosa oral ou genital e tem a capacidade 
de infetar as dendrites e os gânglios sensoriais que enervam estes tecidos onde estabelece latência. 
Estas infeções causam normalmente patologias ligeiras – gengivite, herpes labialis ou herpes genitalis 
– podendo até ser assintomáticas. Porém, infeções com HSV-2 podem causar complicações sérias a 
nível ocular - sendo a primeira causa de cegueira devida a infeção no mundo Ocidental -, neurológico 
- causando meningites e encefalites, especialmente comuns em neonatos – e dermatológico. Estas 
patologias mais severas, associadas à infeção com HSV, ocorrem com maior frequência em pacientes 
imuno-comprometidas, nomeadamente em indivíduos HIV (Vírus da Imunodeficiência Humana) 
positivos. Aliás, a infeção com HSV-2 aumenta 3 a 4 vezes a probabilidade de adquirir HIV e a sua 
disseminação, sendo esta relação recíproca, uma vez que pacientes HIV positivos têm maior 
probabilidade de adquirir HSV-2 e sofrem mais reativações da infeção. Atualmente, existem vários 
agentes com atividade antiviral contra HSV, como o Aciclovir (ACV) e as suas pró-drogas, no entanto, 
tratamentos prolongados com estes compostos podem resultar no desenvolvimento de resistência. De 
acordo com a Organização Mundial de Saúde (OMS) as plantas são a melhor fonte para a obtenção de 
novas drogas e, nas últimas décadas, as plantas medicinais têm sido alvo de vários estudos químicos e 
farmacológicos. Neste estudo foi avaliado o efeito anti-herpético do extrato aquoso de Solidago 
virgaurea, uma planta perianal, membro da família Asteraceae.  
O extrato utilizado foi obtido por decocções de caules e folhas de S. virgaurea e a solução stock foi 
preparada a 100 mg/mL em DMSO. Antes de ser sujeito a testes de actividade anti-herpética foi 
ensaiado o efeito do extracto aquoso na viabiliade de células hospedeiras não infectadas, através do 
método do MTT – um ensaio colorimétrico que se baseia na capacidade de reduzir metabolicamente 
o sal de tetrazolio das células viáveis. Para isso culivaram-se células Vero em placas de 96 poços – em 
meio de cultura com FBS (Soro Fetal Bovino) a 10 % – até à sub-confluência. O meio de cultura foi 
depois substituido por meio com FBS a 2 % e diferentes concentrações de extracto (25 - 250 μg/mL), 
ou meio com FBS a 2 % sem adição de extrato no caso dos testemunhos, e as placas foram incubadas 
24 ou 48 horas a 37 °C. No final do período de tratamento fez-se o teste do MTT para determinação da 
viabilidade das culturas tratadas, por comparação com as culturas não tratadas. Os conteúdos de cada 
iv 
 
poço da P96 foi analisado espectofotometricamente num leitor de placas Elisa. Para caracterizar a 
actividade citotóxica do extracto foram comparadas as absorvâncias obtidas em poços com células 
tratadas e relação a células não tratadas e determinaram-se os parametros CMNC (Concentração 
Máxima Não Citotóxica) - 150 μg/mL - e CC50 (Concentração que inviabiliza 50 % das células) – 177,3 
μg/mL. 
O efeito directo do extracto nas partículas de HSV-2 foi testado através da comparação dos títulos de 
suspensões virais previamente tratadas com 100 μg/mL de extrato em meio com FBS a 2 % com os 
títulos de suspensões não tratadas. O extrato não demonstrou efeito virucida sobre partículas virais 
em suspensão, uma vez que os títulos das suspensões tratadas foram muito semelhantes aos títulos 
dos testemunhos.  
Para testar o efeito do extrato na formação de placas virais infetaram-se células, em placas de 24 
poços, com diluições seriadas de HSV-2. Depois da entrada do vírus – 30 minutos pós infeção – os 
inóculos foram removidos e foi adicionado meio de cultura com FBS a 2 % com ou sem 100 μg/mL de 
extrato, às culturas tratadas e testemunho, respetivamente. No final do período de tratamento – 3 a 4 
horas pós infeção (h p.i.) – foi adicionado meio com FBS e Sephadex a 2 %. A redução de título em 
culturas tratadas foi 71,6 ± 26,8 %, em relação às não tratadas. Foi ainda evidente uma redução no 
diâmetro das placas produzidas nas culturas tratadas. 
Foram também levadas a cabo várias experiências envolvendo a produção de vírus em condições de 
tratamento, em que culturas celulares sub-confluentes foram infetadas com cerca de 3 pfu/célula e 
tratadas com extrato em diferentes concentrações e durante diferentes períodos da infeção. Os títulos 
das suspensões produzidas em condições de tratamento foram comparados com os títulos dos 
testemunhos para o cálculo das percentagens de inibição. A redução média de título – com 
concentrações de extrato não citotóxicas – foi de 93,65 ± 8 %, relativamente a vírus produzido na 
ausência do extrato. Para determinar os parâmetros IC50 e IC90 (concentrações que reduzem o 
rendimento viral em 50 e 90 %, respetivamente) foram produzidas suspensões de HSV-2 em meio com 
FBS a 2 % e diferentes concentrações de extrato (10-175 μg/mL) que foram posteriormente tituladas. 
Os IC50 e IC90 foram calculados através de regressão linear da curva dose-resposta e foram 35,1 e 128,1 
μg/mL, respetivamente. Para investigar a etapa da infeção afetada pelo extrato produziram-se 
suspensões de HSV-2 sob tratamento - com 100 μg/mL de extrato – iniciado em diferentes horas pós 
infeção. Foi observável uma redução da percentagem de inibição do extrato para cerca de 50 % em 
tratamentos começados entre as 3 e as 6 h p.i. e para 0 % a partir das 15 h p.i. Células infetadas tratadas 
e não tratadas, e partículas virais produzidas em ambas as condições, foram observadas por 
Microscopia Eletrónica de Transmissão (TEM), revelando a existência de menos danos, devidos à 
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infeção, em células infetadas tratadas do que em não tratadas e uma quantidade significativamente 
menor de partículas de HSV-2 em suspensões virais produzidas em células tratadas, apesar dos viriões 
produzidos sob tratamento não apresentarem defeitos morfológicos. Por fim foi executada uma 
cinética da infeção em condições de tratamento (e uma cinética testemunho, em condições normais 
de produção viral), para tal, células infetadas – tratadas e não tratadas - foram raspadas para o meio 
de cultura a diferentes horas pós infeção – 2 a 7. O DNA de cada cultura infetada recolhida foi extraído, 
quantificado e submetido a PCR para a deteção de DNA viral. O resultado não permitiu visualizar 
diferenças significativas na quantidade de DNA de HSV-2 em células tratadas e não tratadas, mas 
mostrou um aumento considerável na quantidade de DNA a partir das 5 horas pós infeção. As mesmas 
amostras foram depois utilizadas para PCR em tempo real (qPCR) para avaliar possíveis diferenças na 
quantidade de DNA viral. O resultado mostrou que, embora nas horas iniciais – 3-4 h p.i. – as diferenças 
na quantidade de DNA sejam mínimas, entre amostras de DNA extraído de células tratadas e não 
tratadas, é visível um aumento muito mais lento no número de cópias de DNA viral ao longo da infeção 
em culturas tratadas do que em não tratadas, indicando que a replicação de DNA é afetada durante o 
tratamento com extrato aquoso de S. virgaurea. 
 
Palavras-chave: HSV-2; Atividade anti-herpética; Asteraceae; Células Vero; Citotoxicidade 
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1. Introduction 
 
Herpes simplex viruses (HSV) have been interacting with humans for thousands of years [1] and occur 
worldwide, without seasonal variation [2]. HSV-2 infects more than 500 million people globally, and, 
each year, more than 20 million new cases arise. HSV-2 prevalence increases with age, peaking at 35-
39 years of age, and is generally higher among females than males. It varies substantially by region, 
ranging from about 18 % among women and 13 % among men in Western Europe to 70 % and 55 % in 
Sub-Saharan Africa [3].  
Herpetic lesions at the oro-labial area are typically caused by HSV-1 and genital lesions are commonly 
associated to HSV-2, but, up to 10 % of primary oro-facial herpes infections could be caused by HSV-2 
[4] and, on the other hand, HSV-1 seems to be emerging as the most common cause of primary genital 
herpes [5]. Even though, recurrences of infection by HSV-1 represent less than 5 % of the total cases of 
genital herpes [6]. 
Although HSV typically causes mild diseases it may provoke severe infections in immunocompromised 
patients like HIV seropositives and recipients of solid organ or bone marrow transplants [7]. In fact, an 
important finding in the last decades is that infection with HSV-2 is associated with high susceptibility 
to HIV, and increases its shedding [8, 9]. This relationship is reciprocal, as infection with HIV also 
significantly increases the probability of acquiring HSV-2 and its reactivation has shown itself more 
frequent in HIV-1 positive patients [10].  
Currently, there are several systemic antiviral agents, against herpesvirus, like acyclovir (ACV) and its 
prodrugs – valaciclovir (VACV), famciclovir (FCV), ganciclovir, valganciclovir, cidofovir and foscarnet 
(FOS) – approved by the US Food and Drug Administration (FDA) [11], but, long-term prophylaxis and 
treatment with ACV, VACV or FCV can result in the development of resistance, especially in the 
immunocompromised patients group[7,12] where ACV-resistant HSV prevalence varies between 3.5 % 
and 10 % [7]. 
Plants are still an important source of widely used pharmaceutics [13-19] and Asteraceae family has been 
one of the most studied lately, and specifically its inhibitory activity against HSV was even the subject 
for a few recent works [17, 19-21]. Therefore, and considering the serious negative clinical implications 
that HSV-2 infections cause globally, it’s highly significant to further evaluate anti-viral activities of 
plants of the Asteraceae family, inclusively the anti-herpetic proprieties of Solidago virgaurea, the 
object of this study. 
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1.1. Herpes Simplex Virus 
 
1.1.1. Classification 
Herpesvirus classification was addressed for the first time in 1971 by the International Committee on 
Taxonomy of Viruses (ICTV) where the genus Herpesvirus was established [23]; this genus was later 
elevated to the family Herpesviridae[23].A first attempt of grouping herpesvirus into subfamilies has 
been done based in biological criteria[24]; this division was successful but contained a few 
misclassifications, therefore, further distribution of the subfamilies into genera was based in molecular 
data – genome characteristics, such as size and structure - to a greater extent than before[25].  
Nowadays, the former family Herpesviridae has been elevated to a new order, the Herpesvirales, which 
accommodates three subfamilies - Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae - 
17 genera and 90 species [26]. 
 
1.1.2. Virion Properties 
HSV are large viruses, and their viral particles have complex and characteristic structures. The spherical 
virion includes four major elements: core, capsid, tegument and envelope [27, 28].  
The core consists of the viral genome packed as a linear double-stranded DNA molecule - 150 kpb - 
into the icosahedral capsid. Herpes simplex virus genome has an unusual structure that consists of two 
covalently linked components, long (L) and short (S), and each of these components contains a stretch 
of unique sequences, UL and US, flanked by inverted repeats (Fig. 1 a). The two components can invert 
relative to one another, creating four different types of DNA molecule that differ only in the orientation 
of DNA sequences (Fig. 1 b). The sequence repeat at the left end of UL is designated ab, and the internal 
inverted repeat is designated b’a’. The inverted repeats flanking US are designated a’c’ and ca. Most 
viral genes are present in only one copy per genome; the UL region contains 65 protein coding 
sequences, and the US region contains 14 [28].  
Therefore, HSV contain at least 84 different genes. Presently, most herpes simplex genes are numbered 
sequentially from one end of the unique sequence in which they are found. Thus, genes UL1 to UL56 
are located in the L unique segment and US1 to US12 are located in the S unique segment, and some 
genes lying within the b and c segments have names related to their time of expression or other 
properties. HSV genes can be classified in at least three groups – immediate early (α), early (β) and late 
(γ) -  based on the time of their expression during the replication cycle [2, 28]. 
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Fig. 1 - Genome of herpes simplex virus. a) Organization of unique and repeat sequence elements. Repeat sequence 
elements aare shown in small letters (a,b,c) and elements shwon with a prime are inverted. Unique sequence elements 
are shown in capital letters (UL, US). b) Four isomeric forms of viral DNA with different orientations of the long (L) and (S) 
components due to frequent recombination at the repeated sequence elements. (Source: Acheson 2007) 
 
The bilayered capsid (100-110 nm in diameter) is constructed with six proteins, of which the major 
one, VP5 (150 kDa), makes up the 162 capsomers, that are arranged as 12 pentamers at the vertices 
and 150 hexamers on the faces and edges of the icosahedron. Another capsid protein, VP26, is located 
at the tips of the capsomers. The capsid is enclosed in an envelope that contains at least ten different 
glycoproteins (gB to gM) and several other non-glycosylated membrane proteins [28, 29]. 
The virus envelope has a typical appearance and is thought to be derived from patches of host cell 
nuclear membrane modified by the insertion of virus glycoprotein spikes [29]. 
Unlike in most enveloped viruses, there is a large amorphous mass between the capsid and the 
envelope, called the tegument, which contains about 14 viral proteins like virus host shutoff (vhs), 
VP16 (α-TIF, ICP25), VP11-12, VP13-14 and VP1-2. These proteins are introduced into the cell upon 
infection by herpesviruses, and some of them carry out crucial functions in the virus growth cycle like 
activation of transcription and shutoff of host macromolecular synthesis [28, 29].  
 
1.1.3. Replication 
This virus is characterized by a short – 18 to 24 hours – and cytolytic replicative cycle. Initial attachment 
and penetration of the host cell is mediated via envelope glycoprotein gB that binds to heparan sulfate 
proteoglycans at the cell surface. Afterwards, envelope glycoprotein gD binds to at least two 
alternative receptors: nectin 1 – member of the nectin family of intercellular adhesion molecules – and 
herpesvirus entry mediator (HVEM) – member of the tumor necrosis factor (TNF) receptor family. 
Receptor binding triggers a pH-independent fusion of the viral envelope with the cellular membrane, 
which requires three conserved glycoproteins – gB, gH and gL [28, 29]. 
a) 
b) 
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Fusion results in the introduction of tegument proteins and viral nucleocapsid into the cell cytoplasm 
and the rapid shut down of host macromolecular metabolism. Host DNA synthesis ceases, protein 
synthesis declines rapidly, ribosomal RNA synthesis is reduced and host protein glycosylation ceases. 
Most tegument proteins are believed to act directly or indirectly to produce early shutoff of the host 
macromolecular synthesis and to contribute to the early events of replication, like nucleocapsid 
attachment to nuclear pores and DNA release [29]. 
Nucleocapsids, along with some of the tegument proteins, are transported to the nuclear pores by 
dynein motors along the microtubular network of the cell and, at the nuclear pore, DNA is released 
and enters the nucleus. Empty capsids remain at the cytoplasmic side of nuclear pores for several hours 
until they disintegrate. Viral DNA in the nucleus is circularized, either by direct ligation of the ends or 
by recombination between the a sequences at the ends [28]. 
HSV gene expression is regulated and sequentially ordered as a cascade (α→β→γ). Transcription of 
HSV immediate early (α) genes is carried out in the host nucleus, during the first several hours after 
infection, by cellular RNA polymerase II. Five of the six α gene products are regulatory proteins, 
involved in the regulation of viral and cellular gene expression, and their expression is required for the 
production of all subsequent polypeptide groups. To initiate transcription, tegument protein α-TIF or 
VP16, known as α-transinducing factor, forms a complex with at least two key cellular proteins - Oct-1 
and HCF-1 - which binds to specific response elements in viral DNA that have a central consensus 
sequence – TAATGARATT. These elements, along with binding sequences for other cellular 
transcription factors, are found upstream of the promoters of all α genes, and act as transactivators to 
enhance the transcription of these genes. Transcripts are then transported to the cytoplasm where 
they are translated into five proteins – ICP0, ICP4, ICP22, ICP27 and ICP47 – that are transported back 
to the nucleus where they exert regulatory and activating functions relatively to β genes expression [28, 
29].  
Expression of early – or β - genes results in the production of proteins that work together to carry out 
essential steps in DNA replication. Maximum synthesis rates of these proteins are observed at 5-7 h 
p.i., and when sufficient levels have accumulated within the infected cell, viral DNA replication starts. 
Like other DNA viruses, herpesviruses make their own DNA polymerase that is encoded by a single 
major RNA and has its synthesis during β phase. This enzyme can begin DNA synthesis at any one of 
three viral origins of DNA replication on the herpes simplex virus genome. oriL is located in the middle 
of UL region, and the other two – oriS – are in the c inverted repeats flanking the US region. Replicating 
DNA in infected cells is found as high molecular weight, branched head-to-tail multimers called 
concatemers, suggesting that DNA is made by a rolling circle mechanism, which can produce multimers 
5 
 
from a circular template. However, herpesvirus initially sets up bidirectional replication on the circular 
viral DNA, and only later shifts to rolling circle replication [28, 29]. 
Although γ1 genes can be transcribed in the absence of viral DNA replication their optimal expression 
requires viral DNA synthesis, presumably because of the increase in the number of template DNAs 
available for transcription; in contrast, the transcription of γ2 genes is totally dependent on viral DNA 
synthesis. Late mRNAs enter the cytoplasm for translation into late proteins which include the capsid 
structural proteins that travel back to the nucleus, envelope proteins that are produced in the 
endoplasmic reticulum (ER) and become incorporated in the nuclear membrane and other structural 
and packaging related proteins [28].  
Immature capsids lacking DNA are assembled in the nucleus by accumulation of the major capsid 
protein VP5 and several other proteins around a scaffold formed by three late proteins – VP21, pre-
VP22a and VP24. Viral DNA - in the form of head-to-tail concatemers - is cleaved and stuffed into the 
preformed capsids by the interaction of several viral late proteins with high conserved packaging sites 
– pac1 and pac2 – located in the a sequence near the termini of the DNA. Entry of viral DNA into the 
capsids is carried out by a multimers of UL6 protein located at one vertex of the capsid and involves 
several other nonstructural proteins. DNA packaging is complete when a sufficient length of the DNA 
is introduced and when the packaging machinery encounters the next a sequence along the DNA in 
the same orientation. The packaged DNA is cleaved from the concatemers at a specific site within a 20-
nt direct repeat flanking the terminal a sequence The DNA filled capsids proceed to bud trough the 
modified inner nuclear membrane, into the lumen between the two nuclear membranes, acquiring an 
envelope and a layer of tegument proteins. Virions are then transported from the lumen to the outside 
of the cell [28, 29].  
Three distinct theories account for the mechanism by which virus particles exit the cell. According to 
one theory, virions retain their envelopes and are transported to the Golgi membranes within vesicles 
that bud from the outer nuclear membrane. According to another theory, virions lose their envelope 
by fusion with the outer nuclear membrane, releasing nucleocapsids into the cytoplasm; these 
nucleocapsids subsequently reacquire an envelope by budding into Golgi membranes. In either case, 
the envelope proteins would be glycosylated within the Golgi, and further transport of mature virions 
to the extracellular space is via secretory vesicles. A third theory is based on the observation that 
nuclear pores become enlarged and the Golgi membranes are fragmented during viral replication; 
according to this hypothesis, nucleocapsids exit through the enlarged nuclear pores without an 
envelope and become enveloped at multivesicular bodies derived from fragmented Golgi membranes 
[28, 29]. 
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1.1.4. Clinical Manifestations 
HSV infections cause usually mild pathologies – gingivostomatitis, herpes labialis and herpes genitalis 
– and may be, many times, asymptomatic [28, 30]. Transmission occurs by intimate contact with an 
infected individual either with evident infection or asymptomatic excretion of viral particles, and, after 
primary HSV replication, at the oral or genital mucosa, the virus is able to infect neuronal dendrites of 
sensory ganglia that innervate these tissues and establishes long-term latency, from which it can 
reactivate episodically [31, 32]. 
Besides common herpetic lesions HSV-1 and HSV-2 infections can also result in other skin diseases such 
as herpetic whitlow, which manifests as lesions at the finger tips [33], and eczema herpeticum in patients 
underlying atopic dermatitis – the most common chronic inflammatory skin disease - which may be 
life-threatening for children [34]. 
These viruses are also linked with a variety of ocular complications, mostly epithelial and stromal 
keratitis. HSV can cause stromal opacification and is estimated to be the first cause of blindness due to 
infection in the Western world [35]. 
In addition to establish latent infection in the human nervous system these neurotropic viruses can 
also infect the central nervous system (CNS) causing diseases as meningitis and encephalitis. These 
kinds of infections more often occur in neonates as a result of congenital infection from the mother to 
the new born at birth - even when the mother shows no clinical signs of infection - and can lead to 
severe neurological damage as well as death [36].  
An important finding in the last decades is the fact that infection with HSV-2 increases 3-4 times the 
likelihood of acquiring HIV [8] and considerably increases the dissemination of HIV in the genitalia of co-
infected patients [9].Interestingly this is a reciprocal relationship, since infection with HIV also 
significantly increases both HSV-2 reactivations and the probability of acquiring it [10]. 
 
1.1.5. Therapeutic 
The antiviral therapies for herpes were first approached at Yale, USA in 1959 where a team synthesized 
idoxuridine (IDU) - the first Food and Drug Administration approved antiviral drug - followed by 
trifluorothymidine (TFT), both used to treat Herpes Keratitis (HK) [11]. 
Vidarabine was the first antiviral drug selective enough to be used for systemic treatment of 
herpesvirus (HSV and Varicella zoster virus, VZV) [11, 37]. This drug was later abandoned for reasons 
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including relative insolubility in aqueous medium and rapid deamination, but, most of all, by being 
surpassed by much safer and potent drugs [11]. 
In December 1977 [38] and April 1978 [39] it was announced the discovery of acyclovir (9-(2-
hydroxyethoxymethyl guanine)), a guanosine nucleoside analog that once internalized into infected 
cells is processed into a monophosphorylated form – by HSV thymidine kinase - that is subsequently 
phosphorylated into acyclovir triphosphate by host kinases. In this form ACV thriphosphate is 
incorporated by the viral DNA polymerase disrupting the viral genome replication by a chain 
termination mechanism [40 -42]. 
In vitro, ACV is most potent against HSV-1, approximately half as potent against HSV-2, 1/10th as potent 
against VZV and Epstein-Barr virus (EBV) and least potent against human cytomegalovirus (HCMV)[7]. 
Its main limitation resides in its rather poor oral bioavailability, which led to the development of 
valacyclovir (VACV), an L-valyl-ester prodrug of acyclovir [43, 44]. 
Drug-resistant strains of HSV frequently develop following therapeutic treatment, particularly in 
immunocompromised patients group [7, 12] where its prevalence was reported between 3.5 % and 7 % 
in HIV patients, 2.5 % and 10 % in solid organ transplant patients and 4.1 % and 10.9 % in hematopoietic 
stem cell transplant (HSCT) patients [7]. 
 
1.2. Medicinal Plants 
Evidence for the use of medicinal plants dates back to 60,000 years ago [45] and, in the last decades, 
many pharmacological and chemical studies concerning medicinal plants have been made, with the 
discovery of new therapeutic compounds as a goal [13]. In fact, according to the World Health 
Organization (WHO), these would be the best sources for obtaining a wide variety of drugs and could 
benefit a large population [14]. It has been estimated that more that 50 % of available drugs have, in 
some way, originated from plants [15, 16], examples being morphine, ementine, vincristine and colchicine 
[13]. 
 
1.2.1. Solidago virgaurea 
Solidago virgaurea is a perennial herb member of the Asteraceae family, one of the largest plant 
families with more than 1,600 genus and 24,000 to 30,000 species [46, 47]. This family has a wide 
distribution, existing in every continent, except Antarctic [17, 18]. Solidago L. genus includes about 125 
species that are widely present in the north hemisphere. Solidago virgaurea, commonly designated 
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Goldenrod, being the single member of this genus native in Europe [47, 48]. This species is recognizable 
by its elongated and branched golden yellow flower heads that bloom in summer and has been 
traditionally used to treat urinary tract, nephrolithiasis and prostate diseases [49, 50]. 
 
1.3. Objectives 
Considering the high prevalence of this virus and the serious clinical implications that HSV-2 infections 
may cause to seropositive patients, along with the cooperative relation it can establish with HIV and 
the increasing occurrence of ACV-resistant strains, especially in imunodeficient individuals, the search 
for new and effective treatments is an extremely important matter. As two previous studies [17, 19] had 
concluded that S. virgaurea aqueous extract exhibited anti-herpetic activity, this work aims to further 
characterize its inhibitory effect and investigate the associated mechanisms. 
  
9 
 
2. Materials and Methods 
 
Working with virus and, therefore, with cell cultures demands really strict sterility conditions. Thus, 
most procedures described were prepared in a class II laminar flow cabinet (Biohazard), irradiated with 
U.V. light for 30 minutes before and after each utilization. Most materials used were sterile, either 
disposable or glass, the last ones were sterilized in an autoclave (121 ºC, 15 minutes). All culture media 
were supplemented with antibiotic and kept at 4 ºC. 
 
2.1. Cell Culture 
Cells used were Vero – a continuous lineage isolated from the renal epithelium of the green African 
monkey (Cercopithecus aethiops) – and were obtained from the American Type Culture Collection 
(ATCC) with the reference CCL81. These cells form a monolayer adherent to the flask surface and are 
widely used in virology studies for being permissive for a large variety of virus.  
Cultures were grown in T25 and T75 flasks (Nunc) at 37 ºC in CO2 Independent Medium (Gibco) or 
Dulbecco’s Modified Eagle Medium (D-MEM, Gibco) supplemented with 10 % Fetal Bovine Serum (FBS, 
Gibco), 0.1 % gentamicin sulfate (50 μg/mL) and glutamax (5 μg/mL) with or without a 5 % CO2 
atmosphere,  respectively for each medium. The cultures were observed through an inverted optic 
microscope (Zeiss IM).  
Cells were transferred to a new flask when cultures reached 90 % confluence. The culture medium was 
removed and the cultures washed, twice, with 2.5 mL of PBS (Phosphate Buffered Saline, Gibco), then 
the cultures were trypsinized with 1 mL of trypsin (Gibco) at 37 ºC for 5 minutes. After that, 5 mL of 10 
% FBS culture medium – D-MEM or CO2 Independent Medium - were added to the flask, to disable 
trypsin and homogenize the suspension. Then the cell suspension was distributed accordingly to the 
flask/plate size.  
 
2.2. Aqueous extract stock preparation  
The aqueous extract used in this study was obtained from steams and leafs of the Portuguese 
Asteraceae family member Soligado virgaurea L. The lyophilized extract was supplied by Prof. Dr. Luísa 
Serralheiro from CQB (Centro Química e Bioquímica), FCUL (Faculdade de Ciências da Universidade de 
Lisboa) and kept at -20 ºC. Stock solution was prepared at 100 mg/mL concentration in DMSO 
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(Dimethyl sulfoxide) and kept at -20 ºC, the work solutions were prepared at 10 mg/mL in PBS and kept 
at 4 ºC.  
 
2.3. Virus  
The viruses used in this study were acquired from ATCC, and are wild strains of HSV-2 (Herpes simplex 
type 2 HD) and HSV-1 (Herpes simplex type 1 SC 16). Viruses were kept in suspension with 2 % FBS 
culture medium (D-MEM or CO2 Independent Medium) at 4 ºC. 
 
2.3.1. Virus Production 
The virus suspensions were produced in T75 flasks with sub confluent cell cultures (about 107 cells). 
Culture medium was removed and cells were infected with, approximately, 106 pfu, in a 1 mL volume. 
After the adsorption period – 30 to 60 minutes at 37 ºC – 12 mL of 2 % FBS culture medium (D-MEM 
or CO2 Independent Medium) were added. Flasks were kept at 37 ºC until total cytopathic effect – 
characterized by severe morphological changes in the culture and loss of adherence by most or all the 
cells - could be observed, what takes, usually, 48 to 72 hours of infection.  
Virus suspensions were collected in 15 mL Falcon tubes and centrifuged at 3,000 g for 5 minutes, the 
supernatants were transferred to new, similar, tubes and the pellets were discarded. Produced viruses 
were kept at 4 ºC. 
 
2.3.2. Virus Titration 
To determine the virus titer – the number of plaque forming units (PFU) per mL – each virus suspension 
was serially diluted (1:10) in 2 % FBS culture medium (D-MEM or CO2 Independent Medium) to 10-6. 
Then, in 24 or 48 well plates with sub confluent Vero cell cultures, the 10% FBS culture medium was 
removed and 0.1 mL of each viral dilution was inoculate in duplicates.  
The plates were then incubated for 30 minutes at 37 ºC, to allow viral entry, before the addition of 500 
μL of titration medium – 2 % FBS culture medium with 2 % Sephadex G-75 (Pharmacia Fine Chemicals). 
Plates were kept, absolutely still, at 37 ºC for 2 days – HSV-2 – or 3 days – HSV-1.  
To end the titration, the infected cultures were fixated with 0.5 mL of 10 % (v/v) formaldehyde for 30 
minutes, at room temperature, with stirring. After that, formaldehyde was removed and the plates 
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washed with tap water. The cells were then dyed with 0.2 % crystal violet for 15 minutes, with stirring, 
then the stain was removed and the plates were washed with tap water and dried in an oven at 37 ºC. 
All countable viral plaques were counted and virus titer was calculated by the formula: 
𝑉𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟 (𝑝𝑓𝑢/𝑚𝐿) = #𝑝𝑙𝑎𝑞𝑢𝑒𝑠 × (
1
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛
) × (
1
𝐼𝑛𝑜𝑐𝑢𝑙𝑒 (𝑚𝐿)
) 
 
2.4. Cytotoxicity Assays 
The aqueous extract cytotoxicity was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) method, which is a colorimetric assay that relies on viable cells ability to 
metabolically reduce tetrazolium salt - through mitochondrial enzyme succinic dehydrogenase – into 
purple formazan crystals that accumulate inside the cells. [51] 
Cells were grown in 96 well plates, at 37 ºC, with 10 % FBS culture medium until sub confluence was 
reached. Afterwards, the 10 % FBS culture medium was replaced by 200 μL of 2 % FBS medium with 
different extract concentrations (25 – 250 μg/mL). Wells with 2 % FBS culture medium were kept as 
control. The cell cultures were then incubated at 37 ºC, and regularly observed, for 24 or 48 hours. 
When the incubation periods were concluded all inoculums were removed and the wells were washed 
with 100 μL of PBS.  
Then 100 μL of 0.5 mg/mL MTT solution (Sigma) in 2 % FBS culture medium was added to each well 
and the plate was incubated at 37 ºC for 2 hours, to allow MTT reduction. After that, the solution was 
carefully removed and the formazan crystals were dissolved with the addiction of 100 μL of DMSO. 
Following 30 minute incubation at room temperature the wells content was spectrophotometrically 
analyzed in a microplate reader (Tecan Sunrise) with a 570 nm wavelength and a 630 nm reference 
filter.  
To characterize the extract cytotoxicity parameters as MNCC (maximum non-cytotoxic concentration), 
CC10, CC50 and CC90 (cytotoxic concentration that destroy 10, 50 and 90 % of the cells, respectively) 
were defined, by means of comparison of treated and control wells average absorbance values. 
 
2.5. Virucidal Effect 
The virucidal effect of a compound is its ability to directly inactivate a viral particle, outside or inside 
the host cell. To determine whether or not the aqueous extract exhibit this effect on HSV-2 particles, 
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viral suspensions of 100 – 200 μL (~106 pfu) were treated, in 1.5 mL micro tubes, with different extract 
concentrations for 1-3 hours at room temperature with stirring. A control suspension, with the addition 
of the same volume of PBS, was prepared in parallel to each treated suspension. 
Following the treatment each viral suspension was titrated as well as the respective control. After titers 
determination, the percentage of virus inactivation by each extract concentration was calculated by 
the formula: 
𝑉𝑖𝑟𝑢𝑠 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 = (1 − (
𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟
𝑁𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟
)) × 100 
 
2.6. Effect on HVS-2 replication 
To uncover the extract influence in HSV-2 replication cycle, two kinds of approaches were employed: 
HSV-2 titration under treatment and HSV-2 production under treatment.  
 
2.6.1. Extract effect on viral plaques formation 
HSV-2 was serially diluted (1:10) to 10-6, in 2 % FBS culture medium (D-MEM or CO2 Independent 
Medium) and, in 24 (or 6) well plates with sub confluent Vero cell cultures, the 10 % FBS culture 
medium was removed and 0.1 mL (or 0.4 mL) of each viral dilution was inoculated in duplicates. After 
a 30 minute incubation - to allow viral entry – 0.15 (or 0.7 mL) of culture medium with or without 100 
μg/mL extract were added, respectively, to each treated and control infected cells. 
Plates were then incubated for 10 minutes to 4 hours at 37 ºC, before the addition of 0.5 (or 1.5 mL) 
of titration medium – 2 % FBS culture medium with 2 % Sephadex G-75 – with or without 100 μg/mL 
extract, respectively to treated and control infected cells. 
 
2.6.2. Extract effect on virus yield 
Sub confluent cell cultures, grown in 6 well plates, were inoculated with 3 to 30 pfu/cell of HSV-2 and 
incubated at 4 ºC for 1 to 1.5 hours at a plate rocker to allow viral adsorption to cell membrane. After 
the adsorption period, plates were incubated at 37 ºC for 30 minutes, for viral entry, and inoculums 
were removed. Infected cells were then treated with 500 to 900 μL of 2 % FBS culture medium with or 
without extract (100 μg/mL), and incubated at 37 ºC, in the presence of the extract, for 2 to 24 hours. 
The content of all wells was replaced by 1.4 mL of 2 % FBS culture medium, following the treatment 
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period. Produced HSV-2 were subsequently titrated in 24 well plates as described before, and treated 
suspensions titers were compared to control titers for evaluation of the yield reduction percentage. 
 
2.6.3. IC50 and IC90 determination 
Sub confluent cell cultures, grown in a 12 well plate, were inoculated with 3 pfu/cell of HSV-2 and 
incubated at 4 ºC for 1 hour at a plate rocker. After that, plates were incubated at 37 ºC for 30 minutes 
and then inoculums were removed. Infected cells were then treated with 550 μL of 2 % FBS culture 
medium with or without extract – at variable concentrations -, and incubated at 37 ºC, in the presence 
of the extract, for 4.5 hours. The content of all wells was replaced by 1.4 mL of 2 % FBS culture medium 
following the treatment period. Produced HSV-2 were subsequently titrated in 24 well plates, as 
described before, and treated suspensions’ titers were compared to control titers for evaluation of the 
yield reduction percentage. 
Concentration that reduces viral yield in 50 % (IC50) and concentration that reduces viral yield in 90 % 
(IC90) were calculated through linear regression of the dose-response curve. 
 
2.6.4. Determination of the affected stage during the virus replication 
Sub confluent cell cultures, grown in 6 well plates, were inoculated with 3 pfu/cell of HSV-2 and 
incubated at 4 ºC for 1 hour at a plate rocker. After the adsorption period plates were incubated at 37 
ºC for 30 minutes and inoculums were removed. 800 μL of 2 % FBS culture medium without extract 
were added to each well and, at each treatment starting point – 0.5 to 20 h p.i. -, 800 μL of 2 % FBS 
culture medium with extract (200 μg/mL) were added to treated cultures. Four controls were kept - 
two for treatment starting at 0.5 h p.i., one for 6 h p.i. and one for 20 h p.i. – where 800 μL of 2 % FBS 
culture medium without extract were added at the indicated times. Plates were incubated at 37 ºC, in 
the presence of the extract, for 24 hours. Produced HSV-2 were subsequently titrated in 24 well plates, 
as described before, and treated suspensions titers were compared to control suspensions titers for 
evaluation of the yield reduction percentage. 
 
2.6.5. Comparison with acyclovir inhibition  
Sub confluent cell cultures, grown in 6 well plates, were inoculated with 3 pfu/cell of HSV-2 incubated 
at 4 ºC for 30 minutes at a plate rocker. After adsorption plates were incubated at 37 ºC for 30 minutes 
and inoculums were removed. Infected cells were then treated with 1.5 mL of 2 % FBS culture medium 
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with or without extract/ACV (100 μg/mL), and incubated at 37 ºC, for 48 hours. Products were present 
throughout the whole infection, unlike in most experiments, once ACV requires continuous presence 
to exert maximum inhibitory effect. Produced HSV-2 were subsequently titrated in 24 well plates, as 
described before, and treated suspensions titers were compared to control titers for the evaluation of 
yield reduction percentage. 
 
2.7. Visualization of treated and non-treated infected cells and virus 
suspensions by Transmission Electron Microscopy (TEM) 
 
2.7.1. Infected cells – treated and control – observation by TEM 
Sub confluent Vero cell cultures, grown in 6 well plates, were inoculated with 140 pfu/cell of HSV-2 
and incubated at 4 ºC for 1 hour at a plate rocker. After the adsorption period plates were incubated 
at 37 ºC for 30 minutes, for viral entry. Then, inoculums were removed and each culture was washed 
with 500 μL of PBS. Infected cells were subsequently treated with 1 mL of 2 % FBS culture medium with 
or without extract (100 μg/mL) and incubated at 37 ºC, in the presence of the extract, for 3 hours. The 
content of all wells was replaced by 1.4 mL of 2 % FBS culture medium following the treatment period.  
Infected cells – treated and control – were collected at 14 hours post infection, by scraping to the 
medium with a policemen, to 1.5 mL microtubes and centrifuged at 3,000 g for 5 minutes. 
Supernatants were rejected and pellets were resuspended in 800 μL of 3 % glutaraldehyde in sodium 
cacodylate buffer (0.1 M, pH 7.3), which was replaced, 24 hours later, by cacodylate buffer. Samples 
were kept at 4 ºC until they were sent to Dr. A. P. Alves de Matos (CESAM and Centro de Investigação 
Interdisciplinar Egas Moniz), being then processed and analyzed as described before [52]. 
 
2.7.2. Virus suspensions – treated and control – Negative Staining for TEM 
Sub confluent cell cultures, grown in T75 flasks, were inoculated with 1 pfu/cell of HSV-2 in 2.5 mL of 
virus suspension, and incubated at 4 ºC for 1 hour at a plate rocker. After the adsorption period flasks 
were incubated at 37 ºC for 30 minutes and inoculums were removed. Infected cells were then treated 
with 5 mL of 2 % FBS culture medium with or without extract (100 μg/mL), and incubated at 37 ºC, in 
the presence of the extract, for 2.5 hours. The content of both flasks was replaced by 13 mL of 2 % FBS 
culture medium without extract, following the treatment period. Treated and control suspensions 
were collected 28 hours post infection. 
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Virus suspensions – treated and control – were collected at 28 h p.i. to 15 mL Falcon tubes and 
centrifuged at 3,000 g for 5 minutes. Supernatants were collected in centrifuge tubes and centrifuged 
at 19,000 g for 5 hours, for virus concentration. Supernatants were rejected and the pellet 
(concentrated virus) was resuspended in 100 μL of PBS. 
Samples were kept at 4 ºC until they were sent to Dr. A. P. Alves de Matos (CESAM and Centro de 
Investigação Interdisciplinar Egas Moniz), being then processed and analyzed as described before [52]. 
 
2.8. Kinetics of HSV-2 infection in treated and non-treated cells 
To determine the extract effect on viral DNA replication, sub confluent cultures grown in 12 well plates, 
were infected with 3 pfu/cell of HSV-2, incubated at 4 ºC for 1 hour at a plate rocker and at 37 ºC for 
30 minutes. Then, the viral inoculums were removed and 1 mL of culture medium with or without 100 
μg/mL of extract was added to each treated or control well. 
Each treated and respective control culture was scrapped into the culture medium and collected in a 
1.5 mL microtube, at different hours post-infection – 2 to 7 h p.i. Collected suspensions were 
centrifuged at 3,000 g for 5 minutes, supernatants were rejected and kept at 4 ºC until DNA 
purification.  
DNA was purified using JETQUICK® protocol for the purification of DNA from up to 1 mL of whole blood 
[53] as per manufacturer’s instructions and eluted in 200 μL of DNase free water. Purified DNA samples 
were observed thru electrophoresis in a 0.7 % agarose gel in TBE with 0.005 % EtBr (ethidium bromide), 
to confirm their integrity. DNA concentration was determined for every sample using a NanoDrop® 
Spectrophotometer (Thermo Scientific ND-1000), and 19.41 ng of each DNA sample was used for 
polymerase chain reaction (PCR), to detect HSV-2 DNA.  
Each sample was amplified with HV/Cons primers [54], and reactions were carried out in a total volume 
of 5 µL prepared in ultrapure water with 2.5 µL of 2X MyTaq™ Red Mix (Bioline), 0.5 µM of each primer 
and 1 µL of DNA sample, following manufacturer’s instructions. The amplification program consisted 
of an initial 3 min denaturation at 95 ºC followed by 30 cycles of denaturation – 95 ºC for 30 seconds, 
annealing – 45 ºC for 30 seconds – and extension – 72 ºC for 1 minute. The final extension was carried 
out at 72 ºC for 5 minutes. DNA samples extracted from HSV-2 particles, with JETQUICK® protocol for 
the purification of DNA from up to 1 mL of whole blood [53], were used as PCR positive controls. PCR 
products were visualized by electrophoresis in a 0.7 % agarose gel in TBE with 0.005 % EtBr using 1Kb 
Plus DNA Ladder (Gibco) as a molecular weight marker. The expected amplified fragment size should 
be about 500 bp [54]. 
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To further detect and quantify the amount (copy number) of virus DNA, in treated and non-treated 
cells, 2 ng – in 10 µ of each DNA sample were subjected to real-time PCR (qPCR). qPCR was performed 
with HSV1 HSV2 VZV R-gene® kit from ARGENE® [55] in an Applied Biosystems™ 7500 Instrument, 
according to manufactures instructions - except in the primers addition step, where only HSV-2 
amplification premix was added to the reactions. 
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3. Results 
 
3.1. Cytotoxicity assays 
Results shown were obtained through the MTT colorimetric assay.  
 
3.1.1. Determination of the extract CC50 and MNCC 
Cell viability (Fig. 2, Tab. 1 and Tab. S. 1 in supplementary data) was evaluated by comparison of 
measured absorbance in wells with treated cells – maintained in 2 % FBS medium with different extract 
concentrations - and control cells – maintained in 2 % FBS medium without extract. Cytotoxic 
concentration that destroys 50 % of the cells (CC50) and maximum non-cytotoxic concentration (MNCC) 
were calculated through linear regression of the dose-response curve. 
 
 
Fig. 2 - Graphic representation of the extract cytotoxicity. Values 
represent the mean ± SD of four independent experiments. The black 
arrow indicates the CC50.  
 
According to the calculations the extract CC50 and MNCC are 177.3 and 150.3 μg/mL, respectively. 
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250 4.4 ± 1 
200 8.1 ± 2 
*175 *55.9 
150 100.9 ± 20 
125 102.7 ± 17 
100 99.4 ± 4 
62.50 110.6 ± 2 
50 98.26 ±6 
31.25 110.0 ±1 
25 114.8 ±19 
Tab. 1 – Cell viability percentages obtained in MTT 
assays post 24 or 48 hours of incubation with the 
extract. Values represent the mean ± SD of two 
independent experiments (except *) with 4 replicates. 
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3.1.2. Correlation between FBS concentration in the culture medium and 
cytotoxic effect of the extract 
To investigate possible dissimilarities of the extract cytotoxic effect when it is diluted in medium with 
different serum concentrations, sub-confluent cell cultures were treated with different extract 
concentrations in medium with different FBS concentrations - 0, 2 or 10 % - and controls (cultures 
maintained in medium with the same FBS concentrations, without extract). The extract exhibited 
extremely variable cytotoxicity (Fig. 3, Tab. 2) with variations in the FBS concentration in the culture 
medium. 
 
 
Fig. 3 - Graphic representation of the extract cytotoxicity in different 
FBS concentrations. Values represent the mean ± SD of 1, 3 and 4 
experiments – respectively to 0, 10 and 2 % FBS culture medium – 
with 4 replicates. 
Extract CC50 and MNCC in medium with 2 % FBS were 177.3 and 150.3 μg/mL, respectively, and 123.2 
and 21.2 μg/mL in serum free medium. These values could not be determined in the assays with 10 % 
serum medium. 
 
3.2. Virucidal effect 
Virucidal effect results were obtained by titration of previously treated (with 100 µg/mL of extract) and 
control viral suspensions and comparison of the obtained titers. As noticeable in Fig. 4 and Tab. S. 2 (in 
supplementary data) the extract revealed no meaningful effect against viral particles outside the host 
cell, with a 3.44 ± 2.37 % (mean of 3 experiments) reduction on the virus titer of treated suspensions 
– 7.67 × 106 pfu/mL – relatively to non-treated ones – 7.94 × 106 pfu/mL. 
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Extract 
Concentration 
(μg/mL) 
% Cell Viability 
0 % 
FBS 
10 % FBS 2 % FBS 
250 2 138 ± 30 4 ± 1 
200 3 118 ± 13 9 ± 6 
150 11 56 ± 45 101 ± 20 
125 64 105 ± 12 103 ± 17 
100 62 118 ± 27 99 ± 7 
50 93 93 ± 24 93± 11 
25 97 98 ± 42 110 ± 15 
Tab. 2 - Cell viability percentages obtained in MTT assays 
after 24 or 48 hours of incubation with the extract diluted 
in culture medium with 0, 2 or 10 % FBS. 
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Fig. 4 – HSV-2 suspensions – treated and control - titration results. 
3.3. Extract effect on viral plaques formation 
In order to test the extract effect on HSV-2 plaque formation, cell cultures, grown in 24 or 6 well plates 
were infected with serial dilutions of the virus. After the viral adsorption and entry periods, the 
inoculums were removed and 2 % FBS culture medium – with or without 100 μg/mL of extract – was 
added to treated and control wells. Following the treatment period, 2 % Sephadex titration medium 
was added to each well.  
The extract inhibitory effect was evaluated by comparison of treated and control titers and plaques’ 
diameters.  
 
 
 
 
 
 
 
 
 Control Treated 
10-6 
 
10-5 
10-4 
 Treated Control 
10-7 
 
10-6 
Fig. 5 - HSV-2 suspensions – treated and control - titration results. 
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When added during titration the extract exhibit a 71.6 ± 26.8 % (mean of 3 experiments, see Tab. S. 3 
in supplementary data) reduction in titer and a visible decrease in plaque diameter (Fig. 5) of treated 
versus control conditions. 
 
3.4. Extract effect on virus yield 
Several experiments, involving HSV-2 production under treatment, were performed, to uncover the 
extract effect on virus yield and the involved infection stages. 
It’s noteworthy that a mean yield reduction of 93.65 ± 8 % was calculated using data obtained in 13 
experiments (see Tab. S. 4 in supplementary data) performed in “standard” treatment conditions – 2 
% FBS medium with 100 µg/mL of extract at 0.5 h p.i. during 2 to 4.5 hours. 
 
3.4.1. IC50 and IC90 determination 
To determine the extract IC50 and IC90, HSV-2 was produced in culture medium with different extract 
concentrations, and controls were produced in culture medium without extract. Produced suspensions 
were then titrated, and viral titers (in treated and control cultures) were compared to obtain the 
percentage of yield reduction attributed to each concentration (Tab. 3, Fig. 6). Concentration that 
reduces viral yield in 50 % (IC50) and concentration that reduces viral yield in 90 % (IC90) were calculated 
through linear regression of the dose-response curve. 
  
Fig. 6 - Graphic representation of HSV-2 yield reduction when cell 
cultures were treated with different extract concentrations. Values 
were obtained in one experiment. 
According to the calculations the extract IC50 and IC90 are 35.1 and 128.1 μg/mL, respectively. 
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Extract Concentration (μg/mL)
Concentration 
(μg/mL) 
% Yield 
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175 96.34 
150 90.77 
125 87.99 
100 83.03 
75 84.76 
50 78.86 
40 69.23 
30 60.00 
25 55.56 
20 44.62 
12.5 13.45 
10 1.54 
Tab. 3 - HSV-2 yield reduction percentage when cell 
cultures were treated with different extract 
concentrations.  
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3.4.2. Determination of the affected stage of virus replication 
HSV-2 was produced under treatment conditions - in culture medium with 100 μg/mL of extract – with 
different treatment starting times, and a control suspension was produced in culture medium without 
extract. Yield reduction percentage was determined by titration of the produced virus suspensions and 
comparison of the titers obtained in treated and control conditions. 
 
Fig. 7 - Graphic representation of HSV-2 yield reduction by the extract (100 
μg/mL) in different treatment starting points. Values were obtained in one 
experiment. 
There is a noticeable decrease (Tab. 4, Fig. 7 and Tab. S. 4 in supplementary data) of the extract 
effectiveness when added between 3 to 6 h p.i. and no effect when the treatment is started at 15 h p.i. 
or later (data not shown).  
 
3.4.3. Comparison with ACV inhibition  
To evaluate the mechanisms which mediate the 
virus yield reduction by the aqueous extract, HSV-
2 was produced under treatment conditions with 
both compounds – aqueous extract and ACV – at 
the same concentration – 100 μg/mL. Control 
suspensions were produced in culture medium 
without extract. Each compound yield reduction 
percentage was determined by titration of the 
produced virus suspensions and comparison of 
titers obtained in treated and control conditions. 
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% Yield 
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0.5 91.27 
1 78.55 
3 64.53 
6 46.27 
14 28.74 
Tab. 4 - HSV-2 yield reduction percentage at 
different treatment starting times (h p.i.). 
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Fig. 8 - Graphic representation of HSV-2 yield reduction by 
the extract and ACV (100 μg/mL). Values were obtained in 
one experiment with 2 replicates. 
22 
 
Fig. 8 shows HSV-2 yield reduction percentages in virus produced under treatment with ACV – 95.89 % 
- or S. virgaurea aqueous extract – 97.40 % - , relatively to non-treated virus. The extract exhibited a 
very similar inhibition to the one observed in ACV treatment.  
 
3.4.4. Visualization of treated and non-treated infected cells and virus 
suspensions by Transmission Electron Microscopy (TEM) 
Cell cultures were infected with HSV-2 and treated with 2 % FBS culture medium with or without 100 
μg/mL of extract. Infected cells were then collected at 14 hours post infection and observed by TEM. 
Treated and control viral suspensions were concentrated and observed by negative staining. 
 
Fig. 9 – a-b) Thin section TEM micrographs of HSV2 infected Vero cells processed for TEM at 14 hours p.i. a) Non-treated 
(control). b) Cells treated with 100 μg/mL of the extract. c) HSV-2 virus particle negatively stained with 1 % aqueous uranyl 
acetate. Photos were kindly provided by Dr. A.P. Alves de Matos. 
Negative staining showed a highly reduced amount of virus produced under treatment, as compared 
to controls, with no significant morphogenetic defects (Fig. 9 c), while fine sections with treated 
infected cells (Fig. 9 b) exhibited fewer morphological deficiencies, due to infection, than control 
infected cells (Fig. 9 a). 
 
3.4.5.  HSV-2 Infection Kinetics 
DNA was extracted from Vero cell cultures 
infected with HSV-2 – in treatment and control 
(non-treatment) conditions – at 14 hours post-
infection (h p.i.) and was observed by gel 
electrophoresis (Fig. 10). DNA concentration of 
Infection 
Time (hours) 
DNA concentration (ng/µL) 
Treated Control 
3 26.35 20.34 
4 24.18 19.41 
5 22.39 25.93 
6 22.40 26.74 
7 34.24 31.25 
Tab. 5 - Infected cells - treated and non-treated - DNA 
quantification. 
a b 
c 
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each sample was determined (Tab. 5) using a NanoDrop® and was equalized to 19.41 ng/µL in every 
sample, with DNase free water. PCR was performed to 26 ng of each sample, in order to verify the 
presence of HSV-2 DNA. 
 
Sample 
L 
Treated Controls (Non-Treated) 
h p.i. 2 3 4 5 6 7 2 3 4 5 6 7 
 
Fig. 10 – DNA from treated and non-treated infected cells (from 2 to 7 h p.i.) DNA observed trought gel electrophoresis. 
 
All extracted DNAs showed similar bands when observed in gel electrophoresis (Fig. 10), indicating that 
only cellular DNA is visible.  
 
Sample Treated Controls (Non-Treated) 
L 
PCR 
Controls 
h p.i. 2 3 4 5 6 7 2 3 4 5 6 7 + + - 
 
 
Fig. 11 – Results of PCR for the detection of HSV-2 DNA in infected cells – treated and controls – at different times post 
infection. White arrows indicate the size of two molecular weight marker bands that surround the PCR product bands. 
Although no differences are evident between treated and non-treated PCR products (Fig. 11) this 
experiment shows that, in the applied experimental conditions, viral DNA replication is started 
between 4 and 5 h p.i.  
1018 bp 
506.5 bp 
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The PCR products visualization (Fig. 11) showed that the amplified fragment size was slightly above 
506 bp but under 1018 bp, which fits the expected size. 
 
3.4.6. Quantitative real-time PCR (qPCR) 
To evaluate possible differences between the amounts of viral DNA in treated and non-treated cell 
cultures at different hours post infection, qPCR was performed with 2 ng of the extracted DNA samples 
(Fig. 10). 
 
 
Fig. 12 - Quantification of HSV-2 DNA (copy/mL) in infected cells (treated and non-treated)  at different hours post infection 
(h p.i.). 
 
While at the beginning of infection – 3-5 h p.i. – viral DNA quantities are similar with or without 
treatment, it’s noticeable a slower increase of the copy number in treated relatively to non-treated 
samples, that gets more evident as the infection progresses. 
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4. Discussion 
 
4.1. Extract cytotoxic effect  
When evaluating a product effect against a species or class of micro-organisms it’s important neither 
to overlook the incidence of false-positives nor to discriminate aspecific cell toxicity [56]; this can be 
solved by inclusion of a parallel evaluation of the product effect on host cell lines (cytotoxicity 
evaluation) [57]. 
The lyophilized extract was diluted in DMSO, one of the most frequently used solvents to prepare stock 
solutions, once it eliminates microbial contamination and assures good solubility during the serial 
dilution procedures. It’s important to notice that DMSO is potentially toxic for cells and some 
microorganisms [56]. In fact, DMSO has shown anti-herpetic activity for concentrations above 2 % [58]. 
While previous studies have verified 100 % cell viability for DMSO concentrations under 1 % [56, 58] a 
2012 [19] work showed, through microscopic observation, that DMSO concentrations higher than 0.5 % 
cause cellular modifications. Considering this, all tested extract concentrations were correspondent to 
a lower than 0.5 % concentration of DMSO, to prevent false positives in both cell viability and anti-viral 
activity assays. 
Extract effect in Vero cells viability was evaluated by sub-confluent cell cultures exposition to different 
extract concentrations, at adequate experimental conditions for viral infection – 2 % FBS culture 
medium and 24 or 48 hours incubation at 37 º C. The determined CC50 and MNCC were 177.3 and 150.3 
μg/mL under these conditions (Fig. 2), but varied critically when differences in the FBS concentration 
in the culture medium were introduced, showing greater susceptibility in serum free culture medium 
with a CC50 of 123.2 μg/mL and a MNCC of 21.2 μg/mL (Fig. 3). 
This data shows that, when determining an extract or compound effect on the viability of a virus host 
cell, experimental conditions should be the same as in virus inhibition experiments. However, some 
antiviral studies lack to refer the serum concentration used in cytotoxicity assays [20, 59-61] and others 
describe the utilization of high FBS concentrations [21], what may lead to the employment of cytotoxic 
concentrations in antiviral activity experiments. 
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4.2. Virucidal effect 
Extract direct effect on virus particles was evaluated through the treatment - in non-cytotoxic 
concentrations - of HSV-2 suspensions for 1 to 3 hours, at room temperature, with stirring.  
While previous studies involving this plant aqueous extract [17, 19] concluded that it exhibited strong 
virucidal effect on HSV-2 particles, in the present study it showed irrelevant virucidal effect, since 
treated virus titer reduction relatively to non-treated virus was only 3.44 ± 2.37 % and viral plaques’ 
dimensions were similar (Fig. 4). It’s important to notice that this dissimilarity is probably due to the 
utilization of different batches of extract in the different studies, obtained from plants harvested in 
different years. This shows the discrepancies faced when working with natural products, once the 
compounds produced by plants may vary considerably, depending on environmental factors. 
Further virus production experiments, aiming to analyze the affected stage of the replicative cycle 
stage during treatment, also support the inexistent virucidal activity of the extract, as when the extract 
is added at 15 h p.i. or later, and kept until the end of infection, yield reduction is null (data not shown). 
This suggests that, although viral particles remain several hours in contact with the extract outside host 
cells, it exerts no effect on them showing no virucidal effect. 
 
4.3. Extract effect on plaque formation 
When added during titration - in non-cytotoxic concentrations - the extract showed minor and more 
dissimilar - 71.6 ± 26.8 % - titer reduction of treated relatively to non-treated infected cells than when 
treatment was applied during viral production. This is probably due to the fact that a percentage of the 
cells are still capable of productive infection, yet with lower productions; this may also explain the 
smaller plaques observed in treatment conditions (Fig. 5): a lower number of produced particles will 
infect a lower number of neighbor cells in successive replication cycles. 
These results are consistent with a 2014 study [17] where the extract showed 56 % inhibition and led to 
the production of smaller plaques when added to HSV-2 titration at 100 µg/mL, and a 2012 work [19] 
where it exhibited 86 % inhibition at 300 µg/mL.  
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4.4. Extract effect on virus yield 
Treatment - in non-cytotoxic concentrations - was extremely effective when performed during virus 
production, with a mean yield reduction of 93.65 ± 8% of treated versus non-treated infected cells. 
Yet, viral plaques were morphologically normal, comparatively to controls. 
When evaluating a product antimicrobial proprieties by means of in vitro models the activity of extracts 
or compounds is generally expressed by numeric values - IC50, IC90, etc. – but for a correct interpretation 
of the results a profound knowledge of the model and used protocol is required. Yet, stringent 
endpoint criteria can be defined, being relevant antimicrobial activity set for IC50 values below 100 
µg/mL for natural extracts [56]. Solidago virgaurea aqueous extract IC50 – in treatment during virus 
production - was 35.1 μg/mL, which fits the values described as common endpoints in antimicrobial 
activity. 
The selectivity index (SI) is also an intrinsic component of any antiviral testing and refers to the ratio of 
the maximum drug concentration causing either 50 % or 90 % inhibition of growth of normal cells - 
CC50, CC90 - and the minimum drug concentration at which 50 % or 90 % of the virus is inhibited - IC50, 
IC90 [56]. Accordingly, the extract SI is 5.1 and its noteworthy that this result was founded in cytotoxicity 
experiments performed with 2 % FBS culture medium, while many other studies [20, 59-61] use 10 % FBS 
media, which allows the utilization of much higher product concentrations without cell death, incurring 
in possible results adulteration. 
Furthermore, experiments were performed where treatment was started at different times post 
infection, in order to investigate at which HSV-2 replicative cycle stage does the extract exert its 
inhibitory effect. Results (Tab. 4, Fig. 7) revealed a decrease in the inhibition percentage from 
treatments started at 30 minutes post infection where yield reduction was about 90 %, until 
treatments started at 14 hours post infection where yield reduction dropped to 28.74 %. When added 
at 15 h p.i. or later the extract showed no effect on virus yield. This suggests that the extract may apply 
its inhibitory effect in one or more earlier stages of the infection but after virus adsorption, once the 
effect drops to about 50 % the treatment is started between 3 and 6 hours post infection (Fig. 7). These 
stages may include: nucleocapsid transport to host nuclear pores, viral DNA release into the nucleus, 
immediate early and/or early genes expression and DNA replication [28]. 
Once acyclovir is known to inhibit HSV DNA replication [40-42], an experiment was performed using 
parallel treatments with ACV and S. virgaurea aqueous extract, in order to compare both inhibitory 
effects in virus progeny yield. Results (Fig. 8) shown a very similar inhibition, even a little higher by the 
aqueous extract, but it’s important to highlight that this result was obtained in only one experiment, 
although with two replicates for each treatment. A manifest difference between the two products is 
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the length of the treatment that is required to achieve maximum inhibition; while ACV presence is 
obligatory throughout the entire infection - once it is removed viral replication may carry on - extract 
treatment may be as short as 2 hours (data not shown). This may indicate that only earlier HSV-2 
replication stages are affected and/or that some components of the extract, namely the ones that 
display antiviral activity, remain inside host cell when culture medium is removed. 
To evaluate possible morphological modifications among treated and non-treated infected cells, an 
experiment where treated and non-treated infected cell cultures were collected at 14 hours post 
infection and subsequently observed by TEM was performed. Morphological differences between 
treated and control infected cells were very evident (Fig. 9 a and b) as control cells exhibited 
significantly greater damage, mainly in the nuclear envelope, due to infection than treated cells, 
suggesting that infection was impaired by the treatment. 
Virus particles produced under treatment were also compared with controls by TEM visualization, in 
an experiment where large amounts of HSV-2 were produced, in T75 flasks, with and without 
treatment and were subsequently concentrated. The concentrated viruses were then negatively 
stained with uranyl acetate and counted through TEM. Observations showed that the number of viral 
particles was severely reduced – about 1 % - in suspensions produced in treatment conditions – 100 
µg/mL of aqueous extract - relatively to control suspensions. However, HSV-2 particles produced under 
treatment displayed no morphological decencies (Fig. 9 c). This indicates that the extract inhibitory 
activity leads to an actual reduction in HSV-2 progeny yield, rather than leading to production of 
deficient particles, or other possible inhibitory situation.  
In order to further evaluate the extract action mechanism, a HSV-2 infection kinetics was executed, 
where infected cell cultures - treated and non-treated – were collected from 2 to 7 hours post infection. 
Each infected cell culture DNA was then extracted and observed in gel electrophoresis (Fig. 10), all DNA 
samples presented similar bands, even in later times into the infection, hence only cellular DNA was 
visible in total DNA gel electrophoresis.  
Extracted DNAs were then quantified and equalized to the same DNA concentration – 19.41 ng/µL. A 
PCR for the detection of HSV-2 DNA was then performed with about 25 ng of each total DNA extracted 
and PCR products were observed through gel electrophoresis. While PCR results (Fig. 11) did not supply 
any informative data about the extract inhibitory activity on viral DNA replication - once results were 
quite similar in treated and non-treated samples - they allowed the determination of the time post 
infection at which viral DNA replication occurs, in the applied experimental conditions. This 
information is very relevant to future experiments planning, and interpretation of the obtained results. 
For example, when the beginning of the treatment is delayed to 6 h p.i. the yield reduction drops to 
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less than 50 %, which is consistent with HSV-2 infection kinetics results, as at 5 h .p.i. it’s noticeable a 
major increase in the amount of viral DNA present in the infected cells, which reveals that HSV-2 DNA 
replication stage is already in an advanced phase at that time.  
Accordingly when the treatment is started after viral DNA replication it loses much of its efficiency, 
suggesting that this could be the affected process by the aqueous extract when exerting its antiviral 
activity. To further investigate possible divergences between the HSV-2 DNA replication in treated and 
non-treated cells the same DNA samples were used for real-time PCR to detect and measure the 
amount of viral DNA present in infected cells at the several times post infection – 3 to 7 h p.i. The 
results (Fig. 12) revealed that in shorter infection times – 3 to 5 h p.i. –  no major differences can be 
observed in the amount of viral DNA present in treated and control cells but, as the infection 
progresses, its noticeable that the amount of DNA increases in a severely slower rate in treated 
relatively to non-treated cells. This may indicate that HSV-2 DNA replication may be impaired when S. 
virgaurea aqueous extract is present in the culture medium during infection. 
The overall conclusion of this work is that when infected Vero cells, with HSV-2, are treated with S. 
virgaurea aqueous extract during early infection stages - 0.5 to 5 hours post infection - the virus 
progeny yield is significantly reduced. Moreover, it was evident that viral DNA replication is severely 
impaired when HSV-2 infection occurs under treatment conditions. This antiviral effect may result from 
the inhibition of viral DNA polymerase activity by one or more extract components, leading to the 
termination of HSV-2 DNA replication.  
 
4.5. Further Perspectives 
Further works should focus on the investigation of possible differences in the processes that are part 
of the infection early stage, in HSV-2 macromolecules (RNA, proteins, or DNA) produced under 
treatment comparatively to non-treated suspensions, to assess early genes expression and viral DNA 
replication. 
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6. Supplementary Data 
 
6.1. Extract Cytotoxic Effect 
 
Concentration 
(μg/mL) 
% Cell Viability 
Experiment 1a Experiment 2b Mean 
Standard 
Deviation 
250 5.15 3.68 4.42 1 
200 6.66 9.60 8.13 2 
175 - 55.92 55.92 - 
150 86.71 115.04 100.87 20 
125 114.36 90.93 102.65 17 
100 102.08 96.63 99.36 4 
62.5 109.13 112.15 110.64 2 
50 102.16 94.37 98.26 6 
31.25 111.04 108.93 109.98 1 
25 127.92 101.65 114.79 19 
Tab. S. 1 – Cell viability percentages obtained in MTT assays post 24 (a) or 48 (b) hours of incubation with the extract and 
standard deviation. Cell viability percentages were calculated relatively to controls (non-treated). Each value is the mean 
of 4 replicates. The mean of the two experiments and respective standard deviation is shown. 
 
6.2. Extract Virucidal Effect 
 
  Experiment 1 Experiment 2 Experiment 3 Mean SD 
Treated pfu/mL 1.00 × 107 1.04 × 107 2.64 × 106 7.67 × 106 - 
Control pfu/mL 1.05 × 107 1.05 × 107 2.82 × 106 7.94 × 106 - 
Inactivation % 4.35 1.72 6.45 3.44 2.37 
Tab. S. 2 - Treated - with 100 μg/mL of aqueous extract – and control (non-treated) HSV-2 suspensions titers. Inactivation 
percentages were calculated relatively to controls. 
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6.3. Extract effect on viral plaques formation 
 
  Experiment 1 Experiment 2 Experiment 3 Mean SD 
Treated pfu/mL 8.03 × 107 1.43 × 108 5.36 × 108 2.53 × 108 - 
Control pfu/mL 1.06 × 109 7.00 × 108 9.09 × 108 8.90 × 108 - 
Inhibition % 92.4 79.6 41.0 71.6 26.8 
Tab. S. 3 – Results of three titration experiments where infected cultures were treated - with 100 μg/mL of aqueous extract 
- at 0.5 h p.i. and 2 % Sephadex medium was added 4 h p.i.. Inhibition percentages were calculated relatively to controls. 
 
6.4. Extract effect on virus yield production along infection period 
 
Experiment % Yield Reduction 
Treatment Period 
(h p.i.) 
1 98.86 0.5 - 24.0 
2 77.78 0.5 - 3.5 
3 97.67 0.5 - 3.0 
4 79.35 0.5 - 2.0 
5 78.55 1.0 - 24.0 
6 76.32 0.5 - 2.0 
7 91.71 0.5 - 2.5 
8 46.27 6.0 - 24.0 
9 81.54 0.5 - 16.0 
10 28.74 14.0 - 24.0 
11 89.88 0.5 - 5.0 
12 91.27 0.5 - 24.0 
13 97.40 0.5 - 24.0 
14 64.53 3.0 - 24.0 
15 83.90 0.5 - 2.5 
16 93.97 0.5 - 2.5 
17 98.93 0.5 - 2.0 
Tab. S. 4 – HSV-2 yield reduction percentage of treated - with 100 μg/mL of aqueous extract – relatively to non-treated 
virus suspensions at different treatment periods (h p.i.). 
